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Type 2 diabetesPhosphoprotein enriched in astrocytes-15 (PEA-15) is a cytoplasmic protein that sits at an important junction in
intracellular signalling and can regulate diverse cellular processes, such as proliferation and apoptosis, dependent
upon stimulation. Regulation of these processes occurs by virtue of the unique interaction of PEA-15 with other
signalling proteins. PEA-15 acts as a cytoplasmic tether for the mitogen-activated protein kinases, extracellular
signal-regulated kinase 1/2 (ERK1/2) preventing nuclear localisation. In order to release ERK1/2, PEA-15 requires
to be phosphorylated via several potential pathways. PEA-15 (and its phosphorylation state) therefore regulates
many ERK1/2-dependent processes, including proliferation, via regulating ERK1/2 nuclear translocation. In
addition, PEA-15 contains a death effector domain (DED) which allows interaction with other DED-containing
proteins. PEA-15 can bind the DED-containing apoptotic adaptor molecule, Fas-associated death domain protein
(FADD) which is also dependent on the phosphorylation status of PEA-15. PEA-15 binding of FADD can inhibit
apoptosis as bound FADD cannot participate in the assembly of apoptotic signalling complexes. Through these
protein–protein interactions, PEA-15-regulated cellular effects have now been investigated in a number of
disease-related studies. Changes in PEA-15 expression and regulation have been observed in diabetes mellitus,
cancer, neurological disorders and the cardiovascular system. These changes have been suggested to contribute
to the pathology related to each of these disease states. As such, new therapeutic targets based around PEA-15
and its associated interactions are now being uncovered and could provide novel avenues for treatment
strategies in multiple diseases.
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Since the initial characterisation of phosphoprotein enriched in
astrocytes-15 (PEA-15) almost 20 years ago (Araujo et al., 1993;
Danziger et al., 1995), the unique function of this protein in regulating
intracellular pathways has become increasingly evident. Sitting at a crit-
ical signalling junction which regulates cell behaviour, PEA-15 has the
potential to direct cell phenotypic modulation (Renault et al., 2003;
Valmiki & Ramos, 2009). Recent studies, both biochemical and structur-
al, have begun to further tease out the molecular mechanisms of these
protein interactions in greater detail and led to an enhanced under-
standing of the biology of PEA-15 and its important role inmany cellular
processes. Signiﬁcant evidence has also indicated the involvement of
PEA-15 and PEA-15-regulated intracellular signalling in several differ-
ent diseases including cancer, diabetes mellitus, neurological disorders
and cardiovascular disease. PEA-15 therefore represents a novel and
therapeutically relevant target. This review will examine, in detail, cur-
rentﬁndingswith regard to PEA-15's intracellular functions. In addition,
it will evaluate the potential role of PEA-15 in speciﬁc disease states
with a view to identifying new areas for therapeutic intervention.
2. Structure and signalling of
phosphoprotein enriched in astrocytes-15
PEA-15 was originally identiﬁed in primary cultured astrocytes
following a search for phosphoproteins which might regulate astrocyte
function (Araujo et al., 1993). In this initial study, two phosphorylation
sites were identiﬁed. Subsequent studies demonstrated that these sites
are Ser104 and Ser116 and are preferentially phosphorylated by either
protein kinase C (PKC) at Ser104 or calcium/calmodulin-dependent
protein kinase II (CaMKII) or Akt at Ser116 (Araujo et al., 1993; Estelles
et al., 1996; Kubes et al., 1998). A further study revealed that PEA-15
contained a death effector domain (DED), typically associatedwith pro-
teins involved in the apoptotic cascade, and provided the ﬁrst functional
evidence of a cellular role for PEA-15 (Ramos et al., 1998). This role was
indicated by its ability to block the extracellular signal-regulated kinases
1/2 (ERK1/2)-mediated H-Ras suppression of integrin activation
(Ramos et al., 1998). The DED was required for this blockade but
PEA-15 did not prevent ERK1/2 activation by Ras. This was one of the
ﬁrst examples of a DED-containing protein regulating processes other
than apoptosis. Since these initial studies, multiple investigations have
followed and important details of the structure and function of PEA-15
have now been uncovered.
One of themajor cellular functions of PEA-15 is as an ERK1/2 binding
protein (Formstecher et al., 2001; Hill et al., 2002). ERK1 and ERK2 (con-
ventionally treated as the same enzyme, ERK1/2, due to a high sequence
homology) aremembers of themitogen-activated protein (MAP) kinase
family and are involved in many critical aspects of cell signalling
(Ramos, 2008). Regulation of ERK1/2 is via a canonical cascade involv-
ing several signalling components resulting in the activation of the
MAP kinase kinase, MEK1/2, which phosphorylates ERK1/2 on both
serine and threonine residues. This phosphorylation activates ERK1/2
and results in a wide range of signalling outcomes including cytoplas-
mic interactions (such as with the MAP kinase effector, ribosomal s6
kinase (RSK)) and, following translocation to nucleus, interaction with
the ETS transcription factor, Elk-1 which is an important effector for
ERK1/2-mediated cellular effects such as proliferation (Buchwalter
et al., 2004). The interaction of ERK1/2 with its multiple substrates oc-
curs via two docking domains; theD-domain (common inMAP kinases)
and a docking site for ERK, FXFP (DEF) motif (Roskoski, 2012). As these
enzymes are critical in many different cellular processes, it is perhaps
not surprising that the regulation of ERK1/2 activation (upstream
effects) and the consequences of this activation (downstream actions)
are complex and involve multiple components. These include several
scaffolding proteins which can inﬂuence ERK1/2 activation, e.g. kinase
suppressor of Ras (Yu et al., 1998). Within this complex regulatorysignal, studies have now shown that PEA-15, via its ERK1/2 binding
properties, is likely to have a unique role as a downstream regulator of
the intracellular effects of ERK1/2.
Substantial evidence now demonstrates that PEA-15 acts as a
cytoplasmic “anchor” for ERK1/2 (Formstecher et al., 2001). PEA-15
signalling and its association with ERK1/2 are illustrated in Fig. 1. By
binding to ERK1/2 and sequestering it in the cytoplasm, PEA-15 regu-
lates the outcome of ERK1/2 signalling. Although PEA-15 can enter the
nucleus in limited circumstances for a short time period, it is almost
exclusively conﬁned to the cytoplasm as it contains a nuclear export
sequence (Formstecher et al., 2001). The role of PEA-15 in determining
ERK1/2 localisation, and therefore ERK1/2 signalling outcomes, has now
been demonstrated in a number of different cell types including astro-
cytes (Formstecher et al., 2001; Sharif et al., 2003), ﬁbroblasts
(Gaumont-Leclerc et al., 2004; Buonomo et al., 2012), testicular sertoli
cells (Mizrak et al., 2007), T-lymphocytes (Pastorino et al., 2010),
pituitary gonadotrope cells (Choi et al., 2011) and vascular smooth
muscle (VSM) cells (Hunter et al., 2011). In all these cell types, PEA-15
regulation of ERK1/2 hasmajor effects on cell functionwith implications
for the respective organ systems involved. Cellular overexpression of
PEA-15 leads to decreased ERK1/2 nuclear translocation resulting in
the predicted decreased activation of nuclear substrates of ERK1/2
such as phosphorylation of Elk-1 (Formstecher et al., 2001). Altering
PEA-15 expression levels does not affect the activation of ERK1/2
(non-nuclear) cytoplasmic substrates such as RSK. In fact, PEA-15 acts
as a RSK scaffold facilitating RSK activation by ERK1/2 (Vaidyanathan
et al., 2007). Converse effects on ERK1/2 localisation occur when
PEA-15 expression is knocked down using an RNAi or gene deletion,
producing an increase in ERK1/2 nuclear localisation (Formstecher
et al., 2001; Pastorino et al., 2010; Choi et al., 2011; Hunter et al., 2011).
Importantly, PEA-15 is not an upstream regulator and does not alter
the ability of MEK1/2 to activate ERK1/2 but can directly block ERK1/2
interaction with downstream mediators (Formstecher et al., 2001;
Callaway et al., 2007). Both ERK1/2 and phosphorylated ERK1/2 bind
with equal afﬁnity to PEA-15 (Callaway et al., 2007). Recent studies
have now revealed further details about the binding interaction
between ERK1/2 and PEA-15. PEA-15 binds to ERK1/2 via a bipartite
mode which leads to a tight interaction of these two proteins (Mace
et al., 2013). This includes both theDED and a regionwithin the C termi-
nus of PEA-15 (Hill et al., 2002; Farina et al., 2010; Twomey&Wei, 2012;
Mace et al., 2013). Through this enhanced bipartite binding, ERK1/2 is
tightly coupled and, despite ERK1/2 phosphorylation, ERK1/2 cannot
activate at least some downstream substrates (Callaway et al., 2007).
This is due to PEA-15 binding which blocks the D-peptide-binding site
(or D-recruitment site), the site required for interaction with ERK
substrates. Solving the crystal structures of PEA-15 bound to ERK2 has
revealed further interesting details. Analyses of these structures re-
vealed that PEA-15 actually protects ERK1/2 from dephosphorylation
and in fact acts as a “primer” to hold activated ERK1/2 in a state which
is readied for downstream signalling once ERK1/2 is released from the
PEA-15 complex (Mace et al., 2013). It appears, therefore, that PEA-15
is not merely a scaffold protein for ERK1/2 localisation but in fact an
integral mechanism which can directly regulate ERK1/2 signalling
independent of the recognised canonical activation pathway. This puts
PEA-15 in a unique position in terms of controlling cell function and
suggests that merely assessing ERK1/2 activation as an indicator of the
well-described ERK1/2-mediated outcomes, such as proliferation, is
insufﬁcient.
As PEA-15 is tightly bound to ERK1/2 preventing further downstream
signalling (but not affecting ERK1/2 activation), the release mechanisms
from this inhibitory complex are therefore critical regulatory components.
Several reports have demonstrated that the release mechanism is in fact
the phosphorylation of PEA-15 at Ser104 (phosphorylated by PKC) and
Ser116 sites (phosphorylated by CaMKII or Akt) (Trencia et al., 2003;
Krueger et al., 2005; Renganathan et al., 2005). Phosphorylation of
PEA-15 at least at Ser104 blocks ERK1/2 binding, though phosphorylation
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Fig. 1. The role of PEA-15 in proliferation and apoptosis. PEA-15 has two phosphorylation sites which are preferentially phosphorylated by PKC at Ser104 and CaMKII or Akt at Ser116. PKC
and CaMKII can both be activated by phospholipase Cγ1. PEA-15 is an ERK1/2 binding protein and acts as an “anchor” of ERK1/2 by sequestering it in the cytoplasm, preventing subsequent
translocation into the nucleus. PEA-15 can bind both ERK1/2 and phosphorylated ERK1/2 with equal afﬁnity which is activated by the upstreamMAP kinase kinase, MEK1/2. Phosphor-
ylation of PEA-15 releases ERK1/2 resulting in the activation of the nuclear transcription factor, Elk-1 and proliferation of the cell. PEA-15 contains a DED which upon phosphorylation
promotes the binding of FADD. The association of PEA-15 and FADD prevents FADD-mediated activation of caspases and the formation of the DISC resulting in an inhibition of apoptosis.
The DED of PEA-15 also interacts with PLD1.
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phorylation leads to an increase in the nuclear localisation of ERK1/2 and
activation of nuclear transcription (Krueger et al., 2005; Renganathan
et al., 2005). Using anisotropy methods, one study however suggests
that the afﬁnity of PEA-15 for ERK1/2 in vitro is not altered by PEA-15
phosphorylation (Callaway et al., 2007). The exact mechanism of the
release of ERK1/2 is therefore not completely deﬁned although it is clear
that changes in PEA-15 phosphorylation can alter the physiological
outcomes of ERK1/2 signalling (Krueger et al., 2005; Renganathan et al.,
2005). While further evidence is awaited on the exact nature of the
release mechanisms, it does appear that in terms of ERK1/2 signalling,
PEA-15 is the “trigger”which, when released by phosphorylation, allows
ERK1/2 to translocate to the nucleus and regulate transcription. If this is
indeed the mechanism involved, an interesting scenario is suggested
whereby regulation of two (potentially distinct) pathways may be
required to allow for ERK1/2 signalling; one pathway to stimulate the
canonical activation of ERK1/2 and another to phosphorylate PEA-15.
Indeed, we have shown that knockdown of phospholipase Cγ1 (thereby
inhibiting activation of both PKC and CaMKII) prevents the platelet-
derived growth factor (PDGF)-induced translocation of ERK1/2 (and the
subsequent activation of Elk-1) by blocking PEA-15 phosphorylation but
does not prevent ERK1/2 activation (Hunter et al., 2011). In terms of
ERK1/2 transcription requiring ERK1/2 translocation to the nucleus,
consideration of PEA-15 phosphorylation could therefore be of equal
importance to the ERK1/2 upstream cascade.
While the phosphorylation of PEA-15 probably acts as a trigger-
release mechanism for ERK1/2-mediated cellular outcomes, this
phosphorylation alsomodulates other non-ERK1/2 signalling pathways.
Speciﬁcally, PEA-15 phosphorylation at Ser116 by CaMKII or Akt
promotes the binding of Fas-associated death domain protein (FADD)
to the DED domain of PEA-15 (Condorelli et al., 1999; Kitsberg et al.,
1999). FADD is an essential part of death initiation signalling complex
(DISC) which assembles proteins involved in the apoptotic process
such as caspases (Valmiki & Ramos, 2009). The interaction between
PEA-15 and FADD blocks apoptosis as it prevents FADD-directed activa-
tion of caspases in the DISC (Condorelli et al., 1999; Xiao et al., 2002;
Renganathan et al., 2005; Peacock et al., 2009). Phosphorylated PEA-15 itself can be recruited to the DISC during this process (Xiao et al.,
2002). This anti-apoptotic role of PEA-15 is observed in astrocytes
isolated from PEA-15 null mice which revealed an increased apoptosis
following incubation with tumour necrosis factor alpha (Kitsberg
et al., 1999). T-cells from these same mice, however, did not have
altered apoptotic responses to pro-apoptotic stimuli (Pastorino et al.,
2010). This may represent a level of cell-type speciﬁcity. Regardless,
changing the phosphorylation level of PEA-15 does appear to have an
important role in switching cells into an anti-apoptotic state in several
of the cell types studied to date (Sulzmaier et al., 2012a). Such changes
to cell phenotype have obvious implications in cancer and these will be
explored in greater detail later in this review.
A further protein–protein interaction with PEA-15 has been ob-
served which can have effects on cell function and may be important
in some disease states. PEA-15 binds and interacts with the phospholi-
pase D1 (PLD1), which hydrolyses phosphatidylcholine into the impor-
tant mediator, phosphatidic acid (Zhang et al., 2000). This binding
occurs in the N-terminal of PEA-15 which contains a D-peptide-
binding motif targeted by protein which contain a D-motif including
enzymes such as PLD1 (Viparelli et al., 2008). This interaction is not
dependent on the phosphorylation state of PEA-15 (Sulzmaier et al.,
2012b). Studies have demonstrated that PLD1 activity is increased
when PEA-15 is present, and this is via elevated PLD1 expression (a po-
tential effect on increased PLD1 protein stability) (Zhang et al., 2000).
Such an increase could lead to enhanced downstream effects due to in-
creased levels of phosphatidic acid, for example activation of ERK1/2 via
phosphatidic acid-induced elevation of upstream activators of the
ERK1/2 cascade or increased production of diacylglycerol which acti-
vates PKC isoforms (Besterman et al., 1986; Rizzo et al., 2000). This
may ultimately alter cell phenotype through regulation of proliferation
(Sulzmaier et al., 2012a). The PEA-15 interaction with PLD1 can also in-
hibit insulin-dependent glucose uptake in a skeletal muscle cell line
when PEA-15 is overexpressed (Viparelli et al., 2008).
As PEA-15 is centrally located within the intracellular signalling
landscape, it can be readily appreciated that this protein could poten-
tially be involved in several different disease states. With regulation in
proliferation and apoptosis, in addition to interaction with several
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PEA-15 in several diseases is beginning to emerge, summarised in Fig. 2.
This includes different types of cancerwhere the balance of proliferation
and apoptosis is critical. PEA-15 is overexpressed in diabetes mellitus
and can regulate insulin sensitivity and glucose uptake. Differential
expression of PEA-15 in the brain has also been associated with neuro-
logical disorders such as Alzheimer's and Huntington's diseases. In
cardiovascular disease, our recent study has indicated that PEA-15
may regulate VSM cell proliferation and could therefore be involved in
restenosis following angioplasty in the treatment of atherosclerosis.
Involvement in different aspects of all these disease states raises the
potential of PEA-15 being an effective therapeutic target or prognostic
tool which will be explored throughout this review.
3. Phosphoprotein enriched in astrocytes-15 in cancer
Abnormal cellular signalling is fundamental in cancer progression
and tumourigenesis. PEA-15 was implicated in the dysregulation of
these pathological processes due to its intracellular function. PEA-15
has now been described as both tumour suppressor and promoter due
to its inhibition of proliferation and invasion of some cancerous cells
(Glading et al., 2007; Bartholomeusz et al., 2008; Gawecka et al.,
2012) as well as its upregulation and involvement in resistance to
tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-
mediated apoptosis in several cancer types (Stassi et al., 2005;
Garofalo et al., 2007; Heikaus et al., 2008; Zanca et al., 2008). This
reveals the potential for PEA-15 to be utilised as either a prognostic
marker or a therapeutic target in speciﬁc cancer subsets which could
be dependent, in part, on the phosphorylation status of the protein
(Sulzmaier et al., 2012a).
Cancer is characterised by unregulated cell growth resulting in the
formation of malignant tumours which can invade and destroy
surrounding healthy tissue and can also metastasise in other areas of
the body. Normal quiescent cells transform into active proliferative can-
cerous cells with several acquired capabilities including the generation
of their own growth stimuli resulting in a limitless replicative potential,
resistance to anti-growth signals, apoptosis and destruction by the
immune system, angiogenetic properties, reprogramming of energy
metabolism and the ability to invade adjacent tissue resulting in tumourPEA-1
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Fig. 2. PEA-15 in multiple disease states. PEA-15 acts as both a tumour suppressor and a tum
mediating resistance to TRAIL-induced apoptosis, respectively. PEA-15 is also overexpressed in
inhibits VSM cell proliferation in cardiovascular disease and the levels of PEA-15 are also reducformation and metastasis (Hanahan & Weinberg, 2000, 2011). Genetic
components, environmental factors and lifestyle choices such as
smoking and dietary intake all contribute to the pathogenesis of cancer
causingmutations that produce either oncogenes with a dominant gain
of function or tumour suppressor genes with a recessive loss of function
(Hanahan & Weinberg, 2000). With over 200 different types of cancer
affecting the population worldwide, there is a vital need for a greater
understanding of the disease progression which could result in novel
therapeutic strategies to combat the global burden of cancer.
3.1. Phosphoprotein enriched in astrocytes-15 as a tumour suppressor
Regulation of the ERK1/2 signalling cascade by PEA-15 has been asso-
ciated with several beneﬁcial effects on inhibiting tumour development.
The adenovirus type 5 gene, E1A is known to suppress tumourigenecity
and inhibit overexpression of HER2 in breast and ovarian cancers (Yu
et al., 1993; Chang et al., 1997). PEA-15 is upregulated by E1A resulting
in reduced proliferation in ovarian cancer by inhibition of ERK1/2-
dependent transcription (Bartholomeusz et al., 2006). PEA-15 also
inhibited migration and invasion of cells in breast cancer by its interac-
tion with ERK1/2 resulting in sequestering of ERK1/2 in the cytoplasm
and preventing nuclear translocation (Glading et al., 2007). Moreover,
PEA-15 blocked tumourigenesis in a triple-negative breast cancer
xenograft model by an ERK1/2-dependent mechanismwith overexpres-
sion of PEA-15 resulting in elevated caspase-8-dependent apoptosis
(Bartholomeusz et al., 2010). In glioblastoma cultures, migrating cells
from tumour explants expressed low levels of PEA-15 and this inhibitory
control of PEA-15 on cell motility was through a PKCδ-dependent mech-
anism (Renault-Mihara et al., 2006). PEA-15 was also shown to induce
cellular senescence in humanﬁbroblasts preventing their transformation
(Gaumont-Leclerc et al., 2004).
In addition to impairment of cellmigration and proliferation, PEA-15
expression correlates with good prognosis in neuroblastoma and a 25%
increase in patient survival timewith the highest PEA-15 levels found in
early stage tumours (Gawecka et al., 2012). In astrocytoma, PEA-15
levels were inversely associated with the stage of the tumour
(Watanabe et al., 2010). There is also potential for PEA-15 to be used
as a prognostic tool in ovarian cancer as women with tumours express-
ing high levels of PEA-15 survived for longer (Bartholomeusz et al.,5
Neurological disorders
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vasion of cells and correlates
or”
ancers and involvement in
iated apoptosis
• Differential expression in 
Alzheimer’s disease
• Reduced in mouse models 
of neurodegenerative 
diseases
• Reduced expression induces 
VSM cell proliferation
our promoter in cancer by inhibiting proliferation and invasion of cancerous cells and
type 2 diabetes and PCOS causing altered glucose transport. Reduced PEA-15 expression
ed in various neurodegenerative diseases.
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inhibited migration as well as angiogenesis in vivo which was partially
dependent on β-catenin expression (Lee et al., 2012). This would sug-
gest the potential for PEA-15 as a tumour suppressor and prognostic
marker in cancer with the phosphorylation status of PEA-15 thought
to be inﬂuential in regulating the function of PEA-15 (Sulzmaier et al.,
2012a). However in a recent study, bisphosphorylated PEA-15 was
also shown to sensitise ovarian cancer cells to the chemotherapeutic
agent, paclitaxel by promoting apoptosis via impairment of the
microtubule-destabilising effect of SCLIP, a SCG10-like protein (Xie
et al., 2013).
3.2. Phosphoprotein enriched in astrocytes-15 as a tumour promoter
In contrast to its tumour suppressing function, there is now mount-
ing evidence for an oncogenic role of PEA-15 in several cancer types.
PEA-15 is known to be upregulated in a variety of cancer subsets includ-
ing immortal cancer cell lines (e.g. MCF-7 and HeLa cells) (Condorelli
et al., 1999), malignant pleural mesothelioma cells (Kuramitsu et al.,
2009), breast cancer cells (Stassi et al., 2005), non-small cell lung cancer
(NSCLC) cells (Zanca et al., 2008), glioblastoma (Eramo et al., 2005) and
renal cell carcinomas (Heikaus et al., 2008). Mice overexpressing
PEA-15 also displayed an increase in skin tumourigenesis with a four-
fold increase in papilloma number compared to their wild type litter-
mates (Formisano et al., 2005), suggesting a potential role for PEA-15
in tumour formation and cancer progression.
In NSCLC, PEA-15 has been shown to interact with Rac1, a Rho
GTPase, and aids in Rac1 activation resulting inmodulation ofmigration
and invasion (Zanca et al., 2010). PEA-15 also regulates cellular invasion
in colorectal carcinomas and was observed in well differentiated tu-
mour areas (Funke et al., 2013). PEA-15 interaction with the 67 kDa
laminin receptor (67LR), which has been suggested as a marker for me-
tastasis (Menard et al., 1998), signiﬁcantly increased 67LR-mediated
migration and proliferation (Formisano et al., 2012). Furthermore,
when the proto-oncogene, H-Ras, is constitutively active, PEA-15 was
found to potentiate ERK1/2 signalling and enhance H-Ras-driven trans-
formation of kidney epithelial cells which was mediated, in part, by its
interaction with PLD1 (Sulzmaier et al., 2012b). This highlights an
involvement of PEA-15 in many of the cellular processes which are
critical in tumourigenesis. High ERK1/2 levels were found to correlate
with PEA-15 expression and shorter survival times in patients with
triple-negative breast cancer (Bartholomeusz et al., 2012).
Alterations in apoptotic signalling have also been identiﬁed in sever-
al cancers with changes in expression of apoptosis-related genes
(Debatin & Krammer, 2004). TRAIL preferentially induces apoptosis in
tumour cells opposed to normal healthy cells, suggesting a use as a
tumour-speciﬁc chemotherapeutic agent (Kim et al., 2000). The anti-
apoptotic protein, PEA-15 has been implicated in TRAIL resistance as
well as insensitivity to other forms of apoptosis in several cancer types
resulting in increased cell survival and tumour formation. Increased
levels of PEA-15 were observed in glioblastoma, lymphocytes of pa-
tients with B-cell chronic lymphocytic leukaemia and in tumours of
NSCLC patients; all of which are resistant to TRAIL (Eramo et al., 2005;
Garofalo et al., 2007; Zanca et al., 2008). Similarly, glioma cell lines
resistant to TRAIL were found to have a two-fold increase in PEA-15
expression and inhibition of PKC re-established sensitivity to TRAIL, im-
plicating phosphorylation of PEA-15 in this process (Hao et al., 2001).
TRAIL has four membrane-bound cell surface receptors to regulate the
apoptotic response (Kim et al., 2000). One of these receptors, death re-
ceptor 5 (DR5)was consistently expressed in glioblastoma cell lines and
tumour samples and when activated by TRAIL, recruited FADD and
caspase-8 for the assembly of DISC (Bellail et al., 2010). However,
DR5-mediated DISCwasmodiﬁed by several anti-apoptotic proteins in-
cluding PEA-15 resulting in TRAIL resistance in glioblastoma (Bellail
et al., 2010). Recently, microRNA-212 has been suggested to be a nega-
tive regulator of PEA-15 in NSCLC as overexpression of the microRNAresulting in a reduction in PEA-15 protein levels and increased
TRAIL-mediated apoptosis, suggesting they are inversely correlated
(Incoronato et al., 2010).
In addition to TRAIL resistance, PEA-15 has been implicated in other
mechanisms of cell death. In thyroid cancer, PEA-15 is upregulated by
the cytokines, interleukin (IL)-4 and -10 which causes resistance to
CD95 or Fas activation (Todaro et al., 2006). IL-4 induced the overex-
pression of PEA-15 and other anti-apoptotic proteins in epithelial
cancers such as colon, breast and lung carcinomas resulting in resistance
to apoptosis (Todaro et al., 2008). Upregulation of PEA-15 also led to an
increase in resistance to glucose deprivation-induced apoptosis of
glioblastoma cells and an increase in phosphorylation at Ser116 of
PEA-15was evident in perinecrotic areas (Eckert et al., 2008). However,
protein phosphatase 4-induced apoptosis of human T-cells, which are
important in preventing leukaemia and lymphoma, was found to be
partly mediated by PEA-15 dephosphorylation (Mourtada-Maarabouni
& Williams, 2009).
Pharmacologically targeting the resistance to apoptotic signalling in
cancerous cells could potentially reduce tumour formation. Treatment
with the ﬂavonoid, epigalocatechin-3-gallate, in glioblastoma cells
caused a downregulation in PEA-15 expression through an Akt (PKB)-
dependent mechanism and in combination with TRAIL could be used
to induce apoptosis in tumour cells (Siegelin et al., 2008). The protective
role of PEA-15 on glucose withdrawal was abolished in glioma cells
treated with aMEK1/2 inhibitor suggesting that the pro-survival effects
are mediated through ERK1/2 signalling and could be exploited to help
combat resistance to apoptotic mechanisms (Eckert et al., 2008). In
addition, in prostate cancer cell lines resistant to TRAIL, incubation with
the chemotherapy drug, decitabine, sensitises these cells to TRAIL-
mediated apoptosis, partly through a reduction in anti-apoptotic
proteins including PEA-15 (Festuccia et al., 2008). Microarray analysis
of liposarcoma cultures after treatment with doxorubicin, a potent
chemotherapeutic agent with a limited success rate, was shown to up-
regulate several pro-apoptotic proteins; however, some anti-apoptotic
proteins were also upregulated such as PEA-15 (Daigeler et al., 2008).
Overall, this provides evidence for the role of PEA-15 as both tumour
suppressor and tumour promoter in cancer. Sulzmaier and colleagues
suggested that the switch between these two states was due to the
phosphorylation status of PEA-15 with unphosphorylated PEA-15 dem-
onstrating tumour suppressor qualities while phosphorylation of PEA-
15 induced higher tumour cell survival and resistance to apoptosis.
However, a recent study demonstrated that phosphorylated PEA-15
sensitised ovarian cancer cells to a chemotherapeutic agent (Xie et al.,
2013), suggesting that further investigation of the effect of phosphory-
lation of PEA-15 in inhibiting tumour developmentmight bewarranted.
4. Phosphoprotein enriched in
astrocytes-15 in diseases of the endocrine system
Diseases of the endocrine system are often extremely complex due
to dysregulation of negative feedback mechanisms to maintain
homeostasis resulting in either hypo- or hypersecretion of hormones
or a combination of both. The most common endocrine disease is
diabetes mellitus affecting glucose homeostasis where 10% of people
have type 1 diabeteswhile 90% of those diagnosed have type 2 diabetes.
In addition, polycystic ovary syndrome (PCOS) is one of the most
prevalent endocrine disorders in women, affecting around 1 in 15
worldwide (Norman et al., 2007). This suggests a mounting need for
novel therapeutic targets to combat the increasing occurrence of these
endocrinological disorders within the population.
4.1. Phosphoprotein enriched in astrocytes-15 in type 2 diabetes
Type 2 diabetes is a complex heterogeneous metabolic disorder
which is characterised by chronic hyperglycaemia. The elevated levels
of serum glucose are a consequence of deﬁciencies in both insulin
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impaired insulin regulation of glucose transport and therefore reduced
insulin secretion which is necessary for disease progression (Efendic &
Ostenson, 1993). The major sites of insulin resistance are the liver and
extrahepatic tissues, primarily skeletal muscle and adipose tissue
(DeFronzo et al., 1992; Gerich, 1998). The pathogenesis of type 2 diabe-
tes results from the interaction of genetic and environmental compo-
nents such as obesity, age and lifestyle. Type 2 diabetes displays
polygenic inheritance; however, the gene or genes responsible for this
predisposition are currently unknown. Random genome-wide screens
were utilised in an effort to locate these genes and identiﬁed potential
susceptible loci in different ethnic groups (Hanis et al., 1996; Mahtani
et al., 1996). Mutations in the insulin signalling pathway andmitochon-
drial DNA were also found in diabetic individuals (Kishimoto et al.,
1992; Reardon et al., 1992; Kahn, 1994); however, all of these
abnormalities in gene expression account for only a small proportion
of patients.
Overexpression of the gene encoding PEA-15 in skeletal muscle and
adipose tissue of type 2 diabetic patients, major sites of insulin resis-
tance, was revealed by gene expression studies (Condorelli et al.,
1998). This also resulted in the alternative name for PEA-15 of phospho-
protein enriched in diabetes or PED. Healthy ﬁrst-degree relatives of
type 2 diabetic patients had two-fold higher levels of PEA-15 expression
compared with individuals with no family history of the disease
(Valentino et al., 2006). This effect was also inversely correlated with
insulin sensitivity and independent of sex, age and other dietary condi-
tions (Valentino et al., 2006). Furthermore, offspring of type 2 diabetic
patients display a signiﬁcant genetic risk of developing the disease
(Klein et al., 1996). Mice overexpressing the ped/pea-15 gene were
also found to develop insulin resistance as following insulin administra-
tion, a reduction of only 35% in the plasma glucose levels was observed
after 45 min compared to 70% in control mice (Vigliotta et al., 2004).
Cloning of the promoter region of the human pea-15 gene revealed a
cis-acting regulatory element which binds hepatocyte nuclear factor
4alpha (HNF-4α) which is involved in glucose and lipid homeostasis
(Ungaro et al., 2008). HNF-4α repressed PEA-15 expression in HeLa
cells and HNF-4α silencing correlated with PEA-15 overexpression
resulting in a signiﬁcant reduction in hepatic glycogen content which
could account for the elevated expression levels witnessed in type 2
diabetes (Ungaro et al., 2008; Ungaro et al., 2010). These ﬁndings high-
light the potential signiﬁcance of PEA-15 at the initial onset and also
during disease progression in both mouse models and type 2 diabetic
patients.
Insulin signalling and glucose transport are critical in maintaining
glucose homeostasis and defects in these pathways signiﬁcantly con-
tribute to the pathogenesis of type 2 diabetes. PEA-15 was reported to
alter the expression of two of the major glucose transporter isoforms,
GLUT1 and GLUT4, in both skeletal muscle and adipocytes (Condorelli
et al., 1998). Overexpression of PEA-15 resulted in increased expression
of GLUT1 at the plasma membrane which prevented additional mem-
brane translocation of the transporter after insulin stimulation and
also further inhibited insulin-dependent glucose transport by blocking
GLUT4 membrane recruitment (Condorelli et al., 1998). This higher
basal level of glucose uptake in cells overexpressing PEA-15 impairs fur-
ther insulin action therefore leading to insulin resistance. This is accom-
panied by the PLD-dependent stimulation of conventional PKC isoform,
PKCα by PEA-15 which is constitutively active in these cells and
prevents subsequent activation of the atypical PKCζ by insulin
(Condorelli et al., 1998; Condorelli et al., 2001). The PKCζ isoform is a
primary activator of GLUT4 translocation to the plasma membrane
(Fiory et al., 2009).
As mentioned previously, PEA-15 binds the D4 domain of PLD1with
high afﬁnity which catalyses the hydrolysis of phosphatidylcholine to
phosphatidic acid (Zhang et al., 2000; Viparelli et al., 2008). PLD activity
and the generation of phosphatidic acid have been implicated in signal
transduction as well as vesicular membrane trafﬁcking (reviewed inJones et al. (1999)). Disruption of the interaction between PEA-15 and
PLD1 resulted in reduced PKCα activity, similar to control level, and
the restoration of insulin sensitivity in skeletal muscle cells in vitro
(Viparelli et al., 2008). In addition, insulin sensitivity and secretion
were re-established in vivo in mice overexpressing PEA-15 by adminis-
tration of a recombinant adenoviral vector containing the human D4
cDNA of PLD1 (Cassese et al., 2013). This resulted in overexpression of
the D4 domain which interfered with the PEA-15 and PLD1 association
(Cassese et al., 2013), suggesting the importance of the interaction be-
tween PEA-15 and PLD1 in mediating the detrimental effect on glucose
homeostasis. Mice overexpressing PEA-15 selectively in pancreatic β-
cells also displayed reduced glucose tolerance in vivo but were found
not to be insulin resistant (Miele et al., 2007). Upregulation of PEA-15
affected β-cell function by reducing expression of speciﬁc potassium
channel subunits in the islets (Miele et al., 2007). These mice also
displayed reduced PKCζ activation by glucose and recovery of PKCζ
activity resulted in retrieval of basal levels of potassium channel expres-
sion as well as insulin secretion (Miele et al., 2007).
In addition to the action on glucose homeostasis, upregulation of
PEA-15 has also been implicated in other aspects of type 2 diabetes as
well as complications associated with the disease. PEA-15 overexpres-
sion increased creatine levels and urine volume in mice and elevated
transforming growth factor-β1 (TGF-β1) levels in the kidney and
serum (Oriente et al., 2009). Pharmacological inhibition of PLD and
PKCβ resulted in a reduction in TGF-β1 and ﬁbronectin production, a
component of the extracellular matrix, which could lead to renal
dysfunction and kidney damage, a complication associated with type 2
diabetes (Oriente et al., 2009). TGF-β1 can induce autophagy in certain
cell types and caused upregulation of PEA-15 in skeletal muscle cells
in vitro (Iovino et al., 2012). Atrophic ﬁbres in muscles were also ob-
served in vivo in mice overexpressing PEA-15 which was accompanied
with impaired locomotor activity suggesting muscle atrophy in these
mice (Iovino et al., 2012).
There are currently no pharmacological tools which directly manip-
ulate PEA-15; however, certain drugs have been shown to potentially
mediate their effects through the phosphoprotein. Mice treated with
clozapine, an atypical antipsychotic, caused an increase in PEA-15 ex-
pression in vivo and exhibited reduced PKCγ activity leading to a reduc-
tion in insulin-stimulated glucose uptake (Panariello et al., 2012). In
addition, activation of peroxisome proliferator-activated receptor-γ by
thiazolidinediones signiﬁcantly improves insulin sensitivity in type 2 di-
abetic patients (Nolan et al., 1994; Frias et al., 2000). Pharmacological
activation of peroxisome proliferator-activated receptor-γ in skeletal
muscle cells reduced transcription of thepea-15genewhich could be re-
sponsible for the beneﬁcial effects witnessed with thiazolidinediones
(Ungaro et al., 2012). A more complete understanding of the contribu-
tion of PEA-15 in disease progression as well as further identiﬁcation
of the molecules involved in the signalling pathways could lead to the
development of novel pharmacological therapies in the treatment of
type 2 diabetes.4.2. Phosphoprotein enriched in
astrocytes-15 in polycystic ovary syndrome
Similar to type 2 diabetes, PCOS is a heterogeneous endocrine disor-
der and manifests clinically by hyperandrogenism, chronic anovulation
and the presence ofmultiple cysts on the ovaries inwomen of reproduc-
tive age. Hyperandrogenism or excessive androgen activity is evident by
hirsutism or excessive hair growth, acne and female-pattern alopecia in
conjunction with chronic anovulation resulting in the prevention of
ovulation and oligomenorrhea or infrequent menstruation (Norman
et al., 2007). Polycystic ovaries comprise of an elevated number of
developing follicles and ovarian volume resulting inmenstrual dysfunc-
tion and infertility and can also cause obesity and metabolic syndrome
in affected women.
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oping insulin resistance and type 2 diabetes in premenopausal women
which is independent of obesity which is often associated with both
disorders (Chang et al., 1983; Dunaif et al., 1989). The altered steroid
milieu of PCOS is associated with abnormalities in glucose homeostasis
and insulin secretion with about 30 to 40% of women diagnosed with
glucose intolerance and 10% with type 2 diabetes (Ehrmann et al.,
1999; Savastano et al., 2007). This led to the investigation of PEA-15 ex-
pression in PCOS due to its recognised association with type 2 diabetes.
PEA-15 expression was signiﬁcantly higher in both obese and normal
weight women with PCOS compared with healthy controls and was
also positively correlated with insulin (Savastano et al., 2007). Similar
to type 2 diabetic patients, mRNA and protein levels of PEA-15 were
found to be elevated in omental adipose tissue of women with PCOS
compared to matched controls (Tan et al., 2011). Addition of glucose
and insulin to omental adipose tissue explants ex vivo resulted in an
upregulation of PEA-15 levels whereas metformin, a routinely used an-
tidiabetic drug, caused a reduction in PEA-15 expression (Tan et al.,
2011). This is in agreement with another study which found that after
6 months of treatment with metformin, there was a reduction in
PEA-15 protein levels in obese womenwith PCOS which was also inde-
pendent of body weight (Savastano et al., 2010). In addition, PCOS is
often associated with a deﬁciency in vitamin D which facilitates intesti-
nal absorption of calcium and phosphorus. Lower levels of serum 25-
hydroxyvitamin D, a metabolite produced in the liver by hydroxylation
of vitamin D, and an elevated leptin-to-adiponectin ratio, a biomarker of
insulin resistance, were correlated with PEA-15 expression in women
with PCOS (Savastano et al., 2011). Together, this suggests that an
involvement of PEA-15 in PCOS aswell as in the insulin resistance, com-
monly associatedwith the disease, and by targeting PEA-15 or a compo-
nent of the signalling pathway by pharmacological intervention could
potentially alleviate some of the symptoms of PCOS.
5. Phosphoprotein enriched in
astrocytes-15 in neurological disorders
As PEA-15 was originally discovered as a protein abundant in astro-
cytes, its potential role in neurophysiology would seem to be obvious.
Although earlier studies have investigated the function of PEA-15 in as-
trocytes, this relates mostly to cellular signalling effects on proliferation
and apoptosis predominantly with relevance to cancer (Renault et al.,
2003). Relatively few studies have examined PEA-15 in the context of
neurological functions and non-cancer diseases. PEA-15 is widely
expressed throughout the brain in a variety of different areas and
neuronal cell types (Sharif et al., 2004). Notably, even within the same
neuronal cell types, PEA-15 expression varied suggesting the presence
of subpopulations. The relevance of this is currently unclear. One
study has examined the possible role of PEA-15 in learning (Ramos
et al., 2009). PEA-15 null mice displayed impaired learning in a number
of different spatial learning tasks including the water maze and odour
discrimination and choice. This difference does not appear to be due
to changes in brain morphology but is probably the result of changes
in ERK1/2 signalling as the differences observed in learningwere similar
to those observed in mice with impaired ERK1/2 activation (Blum et al.,
1999). PEA-15 may therefore play a role in learning and memory via its
increased expression in speciﬁc areas, such as the hippocampus.
An indication that PEA-15 may have an important role in the brain
pathology has recently been revealed by proteomic screens for various
neurodegenerative conditions. A recent study examined brains from
an Alzheimer's disease transgenic mouse model (Takano et al., 2012).
Alzheimer's disease is characterised by the formation of plaques
(consisting of β-amyloid peptide) and tangles (made up of tau protein)
which are thought to contribute to the impaired neural function and as-
sociated memory loss. PEA-15 was one of 20 proteins which was signif-
icantly reduced in the hippocampus and cerebral cortex of the
Alzheimer's disease transgenic model (Takano et al., 2012). In contrast,a separate study on the neocortex of a different transgenicmousemodel
of Alzheimer's disease focussed on the neocortical amyloid plaques. In
these plaques, PEA-15 expression was increased compared to controls
and conﬁrmed in humans by studying amyloid plaques from post-
mortem Alzheimer's disease brains (Thomason et al., 2013). These
contradictory changes in PEA-15 expression observed in different
Alzheimer's models may represent variations in distinct brain regions
or neural cell populations as previously observed (Sharif et al., 2004).
Usingmouse models for different neurodegenerative disorders (includ-
ing Huntington's disease, the prion disease Scrapie and a model of im-
paired synaptic transmission), a proteomic study identiﬁed PEA-15 as
a protein with decreased expression in all these disease models (Zabel
et al., 2006). The authors termed this a “nodal” protein indicating that
PEA-15 sits at a critical convergence in intracellular signalling (as
reviewed above) associated with a range of neurological disorders. As
yet no studies have examined the potential role that PEA-15 may play
in any of the mentioned neurodegenerative conditions. How, or indeed
if, PEA-15 is involved in the pathogenesis of these diseases remains to be
determined.
Cerebral ischaemia is a result of an interruption of cerebral blood
ﬂowand canoccur through infarction in the cerebral arteries (ischaemic
stroke). PEA-15 gene expression has been reported to be altered in isch-
aemic neurons. In an in vivo rat model which involves occlusion of the
middle cerebral artery, PEA-15 protein expression was decreased
(Sung et al., 2010; Koh, 2012). The decreased expression could be re-
versed by the anti-oxidant, ferulic acid which may account for some of
the beneﬁcial effects of this reagent. This somewhat contradicts
in vitro experiments with cultured cortical neurons maintained in a
glucose- and oxygen-deprived environment which did not detect any
change in PEA-15 gene expression (Yu et al., 2009).
6. Phosphoprotein enriched in
astrocytes-15 in cardiovascular disease
Considering the intracellular role that PEA-15 has in regulating pro-
liferation and apoptosis, it is perhaps not surprising that, in addition to
cancer, this phosphoprotein could be involved in other diseases where
similar cellular processes occur. With respect to the cardiovascular
system, the principal cell types involved in physiological regulation
are endothelial and VSM cells. PEA-15 has a role in both endothelial
and VSM cell function (Han et al., 2011; Hunter et al., 2011). Cardiovas-
cular disease, anumbrella termwhichencompasses a number of pathol-
ogies associated with the cardiovascular system, typically results from
abnormal regulation of, or damage to, one of these cell types.
In endothelial cells, increased reactive nitrogen species such as
peroxynitrite, is associated with endothelial cell death (Otani, 2009).
Reactive nitrogen species are produced as a result of ischaemia, for ex-
ample following stroke or myocardial infarction. Damage to the endo-
thelial cells could prevent or at least slow recovery of the damaged
myocardium. A recent study has demonstrated that PEA-15 expression
is decreased during ischaemia in vitro as a result of incubation with
peroxynitrite and this possibly contributes to endothelial cell death,
typically observed following ischaemic injury (Han et al., 2011). Over-
expression of phosphorylated PEA-15 prevented this effect suggesting
that elevating PEA-15 expression and/or increasing phosphorylation
therefore could be a potential therapeutic option in ischaemia.
In atherosclerosis, remodelling of the arterial wall occurs due to two
characteristics which are now known to play important pathogenic
roles. These are lipid deposition in the intimal space and the inﬁltration
of inﬂammatory cells. The result of both these processes is the formation
of a lipid-containing plaque with an abundance of inﬂammatory cells.
As the plaque grows, the inward remodelling can become unstable
and lead to thrombosis and/or plaque rupture which ultimately results
in arterial blockage. Inﬂammation is now regarded as a major aspect
of the atherosclerotic process (Hansson & Hermansson, 2011). Initially,
monocytes are recruited to the plaque region as it develops and this is
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likely that much of the inﬂammation which drives vessel remodelling
and plaque stability is regulated by lymphocytes. The role of PEA-15 in
T-lymphocytes has been examined in the PEA-15 null mouse model
(Pastorino et al., 2010). Although these mice do not have any speciﬁc
differences in T-lymphocyte number under non-pathogenic conditions,
an inﬂammatory challenge (in vitro or in vivo) results in an increased T-
lymphocyte proliferation. In addition, there is an increased activation
leading to enhanced production of IL-2. Although this has not yet been
examined in atherosclerotic models, increased T-lymphocyte prolifera-
tion and activation could exacerbate the inﬂammation associated with
atherosclerotic plaques. Indeed, activation of T-lymphocytes is in-
creased when present in the plaque compared with those present in
the blood (Grivel et al., 2011). It is possible that disease-induced chang-
es in PEA-15 expression could be involved in this increased activation.
In cardiovascular disease, VSM cells in the artery wall modulate to-
wards a proliferative phenotype (Owens et al., 2004). This has been
demonstrated both in atherosclerosis and in the vascular injury
response to percutaneous coronary intervention such as balloon angio-
plasty (Marx et al., 2011; Hopkins, 2013). In particular, the restenotic
response is predominantly due to VSM cell proliferation and, despite
the advent of arterial stents to prevent this, re-occlusion still occurs in
~40–50% of cases. The intracellular pathways leading to the switch in
VSM cell phenotype from a fully differentiated contractile cell to a
proliferating state are partly delineated. ERK1/2 is activated by growth
factor receptors, most notably PDGF-β receptor tyrosine kinase which
binds PDGF-BB and this leads directly to the phosphorylation of Elk-1
in the nucleus (Kawai-Kowase & Owens, 2007). Elk-1 interacts with an-
other transcription factor, serum response factor, and represses VSM
cell marker genes such as smooth muscle α-actin and smooth muscle
myosin heavy chain in addition to activating genes associated with pro-
liferation (Kawai-Kowase & Owens, 2007). We have recently demon-
strated that PEA-15 phosphorylation is required for the activation of
Elk-1 in human coronary artery VSM cells (Hunter et al., 2011).
Preventing PEA-15 phosphorylation by either siRNA knockdown of
phospholipase Cγ (to remove the upstream phosphorylation pathway)
or overexpressing nonphosphorylatable PEA-15 mutants, PDGF-BB
stimulation failed to fully phosphorylate Elk-1 and the subsequent re-
pression of the smooth muscle α-actin gene. Furthermore, decreasing
PEA-15 expression led to VSM cell proliferationwhereas overexpressing
wild type PEA-15 inhibited ERK1/2 translocation to the nucleus (Hunter
et al., 2011). Although further research is required to determine the role
in vascular diseases where VSM cell proliferation has a prominent role,
such as restenosis, maintaining PEA-15 expression in VSM cells could be
vasculoprotective.7. Conclusions
PEA-15 is undoubtedly a pivotal and important protein in regulating
major intracellular processes including proliferation and apoptosis. As
PEA-15 is expressed in many different cell types, the ultimate
physiological effects of this regulation are tissue/organ-dependent. It
is therefore not surprising that PEA-15 has been implicated in playing
a key physiological role in many diverse biological systems including
the brain, ovaries, skeletal muscle, blood vessels and immune cells.
From many studies, it is now also apparent that altered PEA-15 regula-
tion and/or expression may be associated with various disease states.
Evidence is now emerging for a potential involvement of PEA-15 in
cancer, type 2 diabetes, PCOS, Alzheimer's disease and cardiovascular
disease. In some of these diseases, particularly cancer and type 2 diabe-
tes, the links to PEA-15 pathology are becoming clearer. Through these
studies, a potential therapeutic target has been partially characterised.
Future studies should provide a more detailed picture for the roles of
PEA-15 in disease states, possibly adding to the list of diseases potential-
ly affected by PEA-15 regulation. This research will start to identifyapproaches to manipulating PEA-15-induced pathological effects
in vivo and the route leading to novel therapies should appear on the
horizon.
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